Ubs Group Ag Aadi Bioscience, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 50,707 shares of AADI stock, worth $171,896. This represents 0.0% of its overall portfolio holdings.

Number of Shares

50,707

Previous 70,365 27.94%

Holding current value

$171,896

Previous $102,000 1.96%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.32 - $2.06 $25,948 - $40,495	-19,658 Reduced 27.94%	50,707 $104,000
Q2 2024 Aug 13, 2024	BUY	$1.46 - $2.31 $72,494 - $114,700	49,654 Added 239.75%	70,365 $102,000
Q1 2024 May 13, 2024	BUY	$1.59 - $2.44 $4,692 - $7,200	2,951 Added 16.62%	20,711 $48,000
Q4 2023 Feb 09, 2024	BUY	$1.97 - $5.41 $17,008 - $46,709	8,634 Added 94.61%	17,760 $35,000
Q3 2023 Nov 09, 2023	SELL	$4.84 - $7.13 $672 - $991	-139 Reduced 1.5%	9,126 $44,000
Q2 2023 Aug 11, 2023	BUY	$6.84 - $8.56 $19,432 - $24,318	2,841 Added 44.22%	9,265 $63,000
Q1 2023 May 12, 2023	BUY	$6.85 - $13.0 $9,583 - $18,187	1,399 Added 27.84%	6,424 $46,000
Q4 2022 Feb 08, 2023	BUY	$11.99 - $14.5 $60,249 - $72,862	5,025 New	5,025 $64,000
Q2 2022 Aug 10, 2022	SELL	$11.57 - $17.92 $465,692 - $721,280	-40,250 Reduced 71.01%	16,434 $202,000
Q1 2022 May 16, 2022	BUY	$16.65 - $24.97 $542,623 - $813,772	32,590 Added 135.26%	56,684 $961,000
Q4 2021 Feb 14, 2022	BUY	$19.32 - $29.02 $460,859 - $692,243	23,854 Added 9939.17%	24,094 $581,000
Q3 2021 Nov 15, 2021	BUY	$25.52 - $41.85 $6,124 - $10,044	240 New	240 $7,000

Others Institutions Holding AADI

# of Institutions

Shares Held

12.6M

Call Options Held

23.8K

Put Options Held

View Full List

About Aadi Bioscience, Inc.

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $71.2M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

More about AADI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account